Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

ABSTRACT:

Background

In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor outcome. We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor outcome.

Methods

In this multicenter, open-label, phase 3 study, we randomly assigned 391 patients with relapsed or refractory CLL or SLL to receive daily ibrutinib or the anti-CD20 antibody ofatumumab. The primary end point was the duration of progression-free survival, with the duration of overall survival and the overall response rate as secondary end points.

Results

At a median follow-up of 9.4 months, ibrutinib significantly improved prog

SUBMITTER: Byrd JC 

PROVIDER: S-EPMC4134521 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature